Key Highlights
- 16.55% is the indicated pre-market move for Dare Bioscience, Inc. (NASDAQ:DARE) on November 18, 2026, taking the indicated price to USD 0.50 from a calculated prior close of USD 0.4290.
- 3.2 million is the approximate third quarter 2026 net loss in USD reported on November 16, 2026, on Revenue of about USD 48,000, with cash of about USD 11.5 million per the Earnings Call summary.
- 9.8 million is the calculated Market Value in USD from 19.67 million shares at USD 0.50, a nano-cap level with elevated Liquidity and dilution risk.
- 851,796 is the additional grant payment in USD announced on November 16, 2026 under an agreement worth up to about USD 10.7 million, with DARE to PLAY prescriptions written across 48 states.
What Moved Dare Bioscience, Inc. (NASDAQ:DARE) in Pre-Market Trading on November 18, 2026 (+USD 0.0710, +16.55%)
The indicated pre-market price of Dare Bioscience, Inc. (NASDAQ:DARE) on November 18, 2026 is USD 0.50, a pre-market move of +16.55%. On a calculated basis, the prior close from the November 17, 2026 regular session was USD 0.4290 (USD 0.50 divided by 1.1655) and the USD move is +USD 0.0710 (price minus prior close). The calculated market value is about USD 9.8 million (19.67 million shares times USD 0.50).
The Rationale: Rebound After Third Quarter Results and Grant News for Dare Bioscience, Inc. (NASDAQ:DARE)
No new company release dated November 18, 2026 was identified in published coverage, so the move reads as a follow-through from the November 17, 2026 session, which came after results. The company reported third quarter 2026 results on November 16, 2026, with revenue of about USD 48,000, a net loss of about USD 3.2 million and cash of about USD 11.5 million, a calculated 3.6 quarters of runway at the third quarter loss rate. The same day it announced a payment of USD 851,796, the second-to-last anticipated Tranche of a grant worth up to about USD 10.7 million, after about USD 5.4 million in 2024 and about USD 3.6 million in November 2025.
Valuation, Liquidity and Risks for Dare Bioscience, Inc. (NASDAQ:DARE)
Fiscal 2025 revenue was USD 1.03 million against USD 9,784 a year earlier, with a loss of about USD 13.40 million. Trailing twelve-month revenue is USD 1.37 million, the net loss is USD 10.99 million and the loss per share is USD 0.78. DARE to PLAY is a topical sildenafil cream for women supplied through a Section 503B outsourcing facility, and company statements flag the risk that the FDA could change the conditions for compounding sildenafil products. Forward-looking language also references going-concern and listing compliance risks. A calculated market value of about USD 9.8 million brings nano-cap risk, including dilution and thin liquidity, and a price of USD 0.50 sits below the USD 1.00 level relevant to Nasdaq minimum bid standards.
Where Things Stand
Dare Bioscience, Inc. (NASDAQ:DARE) is indicated at USD 0.50 in pre-market trading on November 18, 2026, up +16.55% from a calculated prior close of USD 0.4290. The company reported third quarter results on November 16, 2026, with revenue of about USD 48,000, a net loss of about USD 3.2 million and cash of about USD 11.5 million. The calculated market value is about USD 9.8 million. Prescription dispensing of DARE to PLAY began, and grant funding of USD 851,796 was added. Nano-cap shares can reverse quickly, and this article is informational and is not Investment advice.
_11_18_2026_14_40_45_405856.jpg)





Please wait processing your request...